Naloxone controlled release - Algobate

Drug Profile

Naloxone controlled release - Algobate

Alternative Names: Naloxone extended release; Naloxone prolonged release; NLX PRT; NLX-PR

Latest Information Update: 19 Jun 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Algobate AG; Develco Pharma Schweiz
  • Class Antidotes; Morphinans; Small molecules
  • Mechanism of Action Opioid mu receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No
  • Available For Licensing Yes - Constipation

Highest Development Phases

  • Phase III Constipation

Most Recent Events

  • 01 Jun 2017 Phase-III clinical trials in Constipation in Serbia (PO) (EudraCT2017-000657-39)
  • 01 Jun 2017 Algobate initiates enrolment in the phase III NAXOS trial in Constipation in Slovakia (PO) (EudraCT2017-000657-39)
  • 07 Mar 2016 Naloxone controlled release - Algobate is available for licensing in USA as of 07 Mar 2016.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top